BOHR International Journal of Cancer Research最新文献

Paper-Based Biosensor for Early Detection of Oral Cancer 用于口腔癌早期检测的纸质生物传感器

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.001

L. V, N. Mazumder, Karthik G. Vaidya, M. K, S. Sivashankar, K. Shanmugam

{"title":"Paper-Based Biosensor for Early Detection of Oral Cancer","authors":"L. V, N. Mazumder, Karthik G. Vaidya, M. K, S. Sivashankar, K. Shanmugam","doi":"10.54646/bijcr.001","DOIUrl":"https://doi.org/10.54646/bijcr.001","url":null,"abstract":"The significance of paper-based biosensors for the early stage detection of oral cancer and their compatibility with affordable and low-cost diagnostics have been discussed in this article. Oral cancer is a major public health concern in India, and early-stage detection can be a great boon to the public. Among all the available methods for diagnosis, paper-based biosensors have proven to be very efficient in all aspects. It requires a very small volume of sample and very little time, and the process of detection is very simple. The diagnostic platform described here employs a hydrophobic material (wax) to pattern microfluidic channels on a hydrophilic substrate (paper) to detect the desired biomarker in saliva as biological fluid. Biomarker detection in saliva is advantageous because it is a noninvasive and potentially diagnostic sample. One of the primary benefits of using saliva in diagnosis is that sample collection is simple and noninvasive, significantly reducing the discomfort associated with blood collection and the privacy concerns associated with urine collection. The presence of biomarkers such as salivary cotinine and nitrite can be detected on a single paper-based analytical device, allowing for parallel quantification of the biomarkers. Calorimetric assays are used to analyze the biomarkers qualitatively, and ImageJ software is used to analyze the biomarkers quantitatively.","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114210732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case report: Small cell lung cancer presenting as the “sunray sign” in the chest radiograph and recurrent hemoptysis 病例报告:小细胞肺癌在胸片上表现为“阳光征象”并反复咯血

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.2022.05

S. Patil, Neel Tandel, Omprakash Bhangdiya

{"title":"Case report: Small cell lung cancer presenting as the “sunray sign” in the chest radiograph and recurrent hemoptysis","authors":"S. Patil, Neel Tandel, Omprakash Bhangdiya","doi":"10.54646/bijcr.2022.05","DOIUrl":"https://doi.org/10.54646/bijcr.2022.05","url":null,"abstract":"Lung cancer prognosis has not changed in the last few decades due to diagnosis at an advanced stage. The majority of cases with early disease are asymptomatic, and whenever clinical presentations with cough, dyspnea, hemoptysis, or chest pain occur, when these cases have progressed to an advanced stage. Lung cancer tops the list of all causes of cancer-related deaths globally and is ahead of digestive tract malignancies. Small-cell lung cancer (SCLC) has the worst outcome, with survival rates in the range of weeks to months from diagnosis. SCLC is usually manifested as an extensive disease due to its delayed presentation, early metastasis, systemic nature, and poor response to available treatment options. “sunray sign” in chest radiographs is first described in literature and constitutes a hilar mass or radiopacity with inhomogeneous linear opacities spreading toward the periphery like sunrays, which is a marker of interstitial lymphatic involvement due to malignant spread of disease. The “sunray sign” is an indicator of underlying lung malignancy with central airway or main stem bronchus involvement and lymphatic dissemination in linear opacities. In this case report, we have reported a 51-year-old male who presented with cough and hemoptysis with progressive worsening of shortness of breath. Chest X-rays documented round opacities occupying the right hilum with linear opacities emerging toward the periphery in lung parenchyma, showing the typical “sunray sign.” Bronchoscopy was done after clinical stabilization and showed endobronchial polypoidal growth in the right main stem bronchus, causing partial occlusion of the bronchial lumen. Endobronchial needle aspiration (EBNA) cytology and forceps-guided (FB) histopathology are suggestive of “small cell histological type” lung malignancy for the “sunray sign” in our case. A high index of suspicion is a must to rule out underlying malignancy, and bronchoscopy is the “gold standard” test in cases with the sunray sign to confirm the diagnosis.","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131378099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

microRNAs act as a predictor in liver cancer immunotherapy microRNAs作为肝癌免疫治疗的预测因子

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.2023.08

Rui Han

{"title":"microRNAs act as a predictor in liver cancer immunotherapy","authors":"Rui Han","doi":"10.54646/bijcr.2023.08","DOIUrl":"https://doi.org/10.54646/bijcr.2023.08","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Unfortunately, it is frequently diagnosed in advanced stages, limiting the available treatment options. Immune checkpoint inhibitors (ICIs) have shown promise in treating HCC, although their effectiveness varies among patients and can result in undesirable side effects. To enhance treatment outcomes and ensure patient safety, close monitoring and early intervention for side effects are necessary. Consequently, the selection of biomarkers that can predict the response to ICIs in HCC becomes crucial. MicroRNAs, which play a vital role in regulating gene expression in HCC, have emerged as potential biomarkers for predicting treatment response. Some microRNAs have been found to affect ICIs such as CTLA-4 and PD-L1, which are the targets of checkpoint inhibitor therapy. By identifying specific microRNAs that can forecast the response to ICIs, healthcare providers can personalize treatment plans for HCC patients. This tailored approach optimizes resource utilization and minimizes the risk of adverse side effects. Ultimately, this personalized strategy can improve treatment outcomes and enhance the quality of life for individuals with HCC. Thus, the selection of microRNAs capable of predicting the response to ICIs in HCC treatment holds significant importance. It has the potential to enhance patient response rates, decrease adverse effects, and optimize the utilization of healthcare resources.","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125536895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cancer remission due to immune impairment: A review report 免疫损伤引起的癌症缓解:一份综述报告

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.2022.06

R. R

{"title":"Cancer remission due to immune impairment: A review report","authors":"R. R","doi":"10.54646/bijcr.2022.06","DOIUrl":"https://doi.org/10.54646/bijcr.2022.06","url":null,"abstract":"Immune develops in reaction to the presence of a cancerous tumor as it grows to a certain size, rather than through immunological sensitization. This is most likely due to the tumor’s slow growth, giving the immune system more time to acclimate to the new environment. Some immune system components generate “adaptive immunity” in response to a growing malignant growth, while other immune system components aim to prevent cancerous growth from developing. The immune system’s protective arm is often responsible for assuring the advancement of malignant growth. Because of the immunological tolerance, the immune system may misidentify the malignant growth as a component of the body with which it is already acquainted, adding to the protective impact. Immunological paralysis may be caused by a severe infection or a tumor mass that is excessively large. Both of these variables may lead immune system components entrusted with safeguarding the body against malignant growths to become overburdened and shut down. Immunological paralysis may be caused by any of these reasons. At this stage, several immune system components are no longer capable of providing any protection against the creation of malignant tumors. At this point, it is projected that the malignant disease will go into remission after a simple acute inflammation, followed by remission. This is because the inflammation would be followed by remission.","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"121 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129027456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound-Targeted Microbubble Destruction (UTMD): Targeted Nanodrug Delivery in Cancer 超声靶向微泡破坏(UTMD):肿瘤靶向纳米药物递送

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.003

Surya V, Mohammed Manaz, Preethi Sharon, K. Shanmugam

引用次数: 1

TNM system for staging esophageal cancer: A narrative review 食管癌分期的TNM系统综述

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.2022.04

Téllez Almenares O

{"title":"TNM system for staging esophageal cancer: A narrative review","authors":"Téllez Almenares O","doi":"10.54646/bijcr.2022.04","DOIUrl":"https://doi.org/10.54646/bijcr.2022.04","url":null,"abstract":"Cancer is a critical health concern worldwide, and this chronic disease is gradually growing. In 2020 alone, 19,292,789 new cases were reported globally; by 2025, this figure is expected to rise to 21,618,445. Among the various cancers, esophageal cancer is considered one of the most aggressive, with a poor survival rate. It currently ranks eighth in incidence and sixth in mortality among all cancers, and its frequency and mortality are progressively increasing, with 604,100 new cases and 5,44,000 deaths by 2020. Several staging systems have been proposed for esophageal cancer, including the Ellis, Japan Esophageal Society, and AJCC/UICC systems. However, since the AJCC/UICC established their staging criteria, these have been the most widely used and accepted by the medical community. The different AJCC Cancer Staging Manual editions have progressively incorporated changes in the esophageal cancer staging as our understanding, which has been exponentially influenced by various conventional diagnostic means. The TNM staging system’s editions are updated periodically, but how much have they changed since the first edition? What have been the main changes introduced in each edition concerning esophageal cancer? This narrative review aims to answer these questions through a thorough and comparative analysis of each TNM addition. The esophageal cancer staging has changed with each TNM edition, allowing a better understanding of it and applying better therapeutic methods. The last two editions have introduced significant changes with the incorporation of non-anatomical categories into the staging grouping and the addition of a classification for patients undergoing neoadjuvant therapy","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133950730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case report of desmoid tumor involving the head and neck region: challenges in diagnosis and treatment 累及头颈部的硬纤维瘤1例:诊断和治疗的挑战

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.2023.07

Nilesh Deshmane, Adnan Calcuttawala, Sharad Desai

引用次数: 0

Modern Advancement in Diagnosis and Treatment of Clinical Cancer 临床肿瘤诊断与治疗的现代进展

BOHR International Journal of Cancer Research Pub Date : 1900-01-01 DOI: 10.54646/bijcr.002

Deepika Kumari, Dikshansha Rohilla, Anamika Chaudhary, K. Shanmugam

{"title":"Modern Advancement in Diagnosis and Treatment of Clinical Cancer","authors":"Deepika Kumari, Dikshansha Rohilla, Anamika Chaudhary, K. Shanmugam","doi":"10.54646/bijcr.002","DOIUrl":"https://doi.org/10.54646/bijcr.002","url":null,"abstract":"Cancer is one of the leading causes of mortality worldwide with hundred types of cancer that affect humans. The most spreading cancer globally is breast, prostate, lung, stomach, and colorectal cancers and nonmelanoma skin malignancies. Early detection of these transformations in the cell can improve the prognosis of cancer cases. Oncological screening and methods include ultrasound, MRI, digital mammography, CT scan, and magnetic resistance spectroscopy. Other techniques such as immunohistochemistry, RT-PCR, and micro-array are used for the diagnosis of cancer. Precision medicine is currently the subject of extensive research for the benefit of cancer therapy in the future. Chemotherapy, radiation therapy, immunotherapy, and hormone therapy are the most often administered treatments to patients. The greatest treatment for cancer is also a stem cell transplantation, but it must come after less effective treatments to prevent blood loss and restore the patient’s health. The nanoparticles have been considered the best tumour-targeting vehicle. The recent nano-scale vehicles including polymeric nanoparticles, liposomes, nano-shells, and dendrimers have been used as conjugates.","PeriodicalId":319224,"journal":{"name":"BOHR International Journal of Cancer Research","volume":"98 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124688508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0